Home › Trial NCT05417750
A Phase I Study of GC101 TIL in Advanced Solid Tumors
- Trial IDNCT05417750
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorShanghai Juncell Therapeutics
- Enrollment43
- Start date2022-10-12
- ConditionsTumor Infiltrating Lymphocytes · Safety · Advanced Solid Tumor · Immunotherapy · Efficacy · Adverse Drug Event
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.